St. Jude Medical says RESPECT trial not statistically significant

theflyonthewall.com

St. Jude Medical announced results from its RESPECT trial, which studied the AMPLATZER PFO Occluder in the prevention of recurrent cryptogenic stroke. Evidence presented at a late breaking trial session during the 24th Annual Transcatheter Cardiovascular Therapeutics scientific symposium, shows that the primary analysis was not statistically significant but trended towards superiority, while additional analyses demonstrated superiority. Stroke risk reduction was observed across the totality of analyses with rates ranging from 46.6% - 72.7%. St. Jude said.

Rates

View Comments (0)